Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $18, up from $4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune announces FDA acceptance of BLA resubmission of RP1
- Replimune announces new ad hoc analysis from IGNYTE phase 2 cohort of RP1
- Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Replimune downgraded to Underweight from Neutral at JPMorgan
- Replimune Group Completes FDA Meeting on RP1 Application